1. Langtry HD, Brigadoon RN. Clarithromycin: a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997; 53: 973–1004.
2. Peters DH, Clissold SJ. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117–64.
3. McCarty JM. Clarithromycin in the management of communityacquired pneumonia. Clin Ther 2000; 22 (3): 281–94.
4. Bogossian M. Use of clarithromycin for respiratory infections in general practice. Rev Bras Med 1995; 52: 500–9.
5. Farhat CK. Use of clarithromycin in respiratory infections in pediatrics. Mod Pediatr 1995; 31: 1–8.
6. Endo LH. The use of clarithromycin in respiratory infections in general practice. Otorrinolaringologia 1995; 2: 1–8.
7. Lerner FE, Caliendo G, Santagada V et al. Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. Int J Clin Pharmacol Ther 2000; 38 (7): 345–54.
8. Lohitnavy M, Lohitnavy O, Wittaya-areekul S et al. Average bioequivalence of clarithromycin immediate released tablet formulations in healthy male volunteers. Drug Dev Ind Pharm 2003; 29 (6): 653–9
9. Lohitnavy O, Lohitnavy M, Sareekan K et al. Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers. Biopharm Drug Dispos 2003; 24 (6): 229–31.
10. Nightingale CH. A survey of the quality of generic clarithromycin products from 13 countries. Clin Drug Invest 2000; 19: 293–305.
11. Nightingale CH. A survey of the quality of generic clarithromycin products manufactured in Slovenia and Israel. Adv Ther 2000; 17: 167–78.
12. Morgan DK, Brown DM, Rotsch TD et al. A reversed-phase high-performance liquid chromatographic method for the determination and identification of clarithromycin as the drug substance and in various dosage forms. J Pharm Biomed Anal 1991; 9: 261–9.
13. Morgan DK, Cugier P, Marello B et al. Impurity profiling of clarithromycin using high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1990; 502: 351–8.
14. Davidson AG, McCallum A. A survey of the stability of omeprazole products from 13 countries. Drug Dev Ind Pharm 1996; 22: 1173–85.
15. Ishii K, Katayama Y, Itai S, et al. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. Chem Pharm Bull 1995; 43: 1943–8.
16. Qureshi SA, McGilveray IJ. Assessment of pharmaceutical quality of furosemide tablets from multinational markets. Drug Dev Ind Pharm 1998; 24: 995–1005.
17. CPMP/ICH/282/95 Step 4, Consensus Guideline, 6 November 1996.
18. USP 27, The United States Pharmacopeia, The United States Pharmacopeial Convention Inc., Rockville (MD), 2004.
Авторы
C.H.Nightingale
Center for Anti-Infective Research and Development, Hartford Hospital and University of Connecticut School of Pharmacy, Hartford, Connecticut, USA